Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 5/20 | 0.69 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.56 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 6/20 | 0.54 |
| ▸ | HTR1A | P08908 | 4/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.54 |
| ▸ | HTR3B | O95264 | 4/20 | 0.54 |
| ▸ | HTR3A | P46098 | 4/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.54 |
| ▸ | HTR2C | P28335 | 4/20 | 0.54 |
| ▸ | THRB | P10828 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25493027 | 0.94 | ADRB1 (0.61) | ADRB1TGFBR1ACVR1HTR7HTR1A | |
| SCHEMBL25493025 | 0.85 | KMT2A (0.56) | ADRB1HTTALDH1A1MAPT | |
| SCHEMBL5761993 | 0.84 | ADRB1 (0.64) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL25492992 | 0.83 | KMT2A (0.55) | ADRB1HTTALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL6501617 | 0.83 | ADRB1 (0.62) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL6414607 | 0.83 | ADRB1 (0.62) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL25492995 | 0.82 | ADRA2C (0.57) | HTR3AHTR2CHTTDRD2DRD3 | |
| SCHEMBL7838014 | 0.81 | ADRB1 (1.00) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL379449 | 0.81 | ADRB1 (1.00) | ADRB1HTR7HTR1AHTR3EHTR3B | |
| SCHEMBL4515500 | 0.81 | ADRB1 (0.66) | ADRB1TGFBR1ACVR1HTR1AHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | BIOPROJET (FR) | 2008-09-04 | — | — | US | disclosed |
| EP-0850222-B1 | PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAMJIN PHARM CO LTD (KR) | 2003-05-28 | — | — | EP | disclosed |
| US-6518273-B1 | 2-aryl indole derivative as antagonists of tachykinins | MERCK SHARP & DOHME LTD. | 2003-02-11 | — | — | US | disclosed |
| WO-2000051984-A1 | 2-ARYL INDOLE DERIVATIVES AS ANTAGONISTS OF TACHYKININS | MERCK SHARP & DOHME LIMITED (GB) | 2000-09-08 | — | — | WO | disclosed |
| US-6028195-A | AN ANTITUMOR AGENT WITH VERY LOW TOXICITIES | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2000-02-22 | — | — | US | disclosed |
| EP-0850222-A1 | PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 1998-07-01 | — | — | EP | disclosed |
| WO-1998000402-A1 | PIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | TYR, TYRO3, TH | ADRB1 2933/4885TGFBR1 2015/4885ACVR1 692/4885 |
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | SLC6A3, ADRB3, PRLHR | ADRB1 29/4885TGFBR1 3267/4885ACVR1 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.